Alternative Nonsteroidal Antiandrogen Therapy for Advanced Prostate Cancer That Relapsed After Initial Maximum Androgen Blockade-Reference-Cited by-同舟云学术

Alternative Nonsteroidal Antiandrogen Therapy for Advanced Prostate Cancer That Relapsed After Initial Maximum Androgen Blockade

Published:2008-09 Issue:3 Volume:180 Page:921-927
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Suzuki Hiroyoshi¹,Okihara Koji¹,Miyake Hideaki¹,Fujisawa Masato¹,Miyoshi Susumu¹,Matsumoto Tetsuro¹,Fujii Motohiro¹,Takihana Yoshio¹,Usui Tsuguru¹,Matsuda Tadashi¹,Ozono Seiichiro¹,Kumon Hiromi¹,Ichikawa Tomohiko¹,Miki Tsuneharu¹,

Affiliation:

1. Departments of Urology, Graduate School of Medicine, Chiba University (HS, TI), Chiba and School of Medicine, Kyoto Prefectural University (KO, TM), Kyoto, Japan

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference20 articles.

1. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials;Lancet,2000

2. Prostate specific antigen decline after antiandrogen withdrawal: the FLT withdrawal syndrome;Kelly;J Urol,1993

3. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583);Small;J Clin Oncol,2004

4. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer;Scher;Urology,1996

5. Androgen receptor involvement in the progression of prostate cancer;Suzuki;Endocr Rel Cancer,2003

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic factors for non‑metastatic castration‑resistant prostate cancer treated with androgen receptor signaling inhibitors;Molecular and Clinical Oncology;2024-08-08

2. PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer;Scientific Reports;2024-07-03

3. Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies;ESMO Open;2024-07

4. PSA Doubling Time 4.65 months as an Optimal Cut-off of Japanese Nonmetastatic Castration-Resistant Prostate Cancer: Multi-institutional Study of Japanese Urological Oncology Group (JUOG);2024-04-22

5. Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study;Japanese Journal of Clinical Oncology;2024-02-01